Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC
/in Dendritic Cells, International Publications, NSCLC /von 2017-12-21 / BMC Cancer 2017 12;17(1):884Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC
/in Dendritic Cells, International Publications, NSCLC /von 2017-09-21 / Int. Immunopharmacol. 2017 Nov;52:197-202Phase I Trial of Intratumoral Injection of Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8 T-cell Infiltration
/in Dendritic Cells, International Publications, NSCLC /von 2017-05-03 / Clin. Cancer Res. 2017 Aug;23(16):4556-4568Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis
/in Dendritic Cells, International Publications, NSCLC /von 2016-07-22 / Cancer Immunol. Immunother. 2016 09;65(9):1099-111Thermosensitive liposomal cisplatin in combination with local hyperthermia results in tumor growth delay and changes in tumor microenvironment in xenograft models of lung carcinoma
/in Hyperthermia, International Publications, NSCLC /von 2016-06-16 / J Drug Target 2016 11;24(9):865-877Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2016-04-21 / Radiat Oncol 2016 Apr;11:60Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib-effective patients with advanced NSCLC
/in Hyperthermia, International Publications, NSCLC /von 2016-03-24 / Thorac Cancer 2016 Jul;7(4):422-7Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2016-02-24 / Oncol Lett 2016 Apr;11(4):2605-2610Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy
/in International Publications, Newcastle Disease Virus, NSCLC /von 2015-11-15 / Am J Cancer Res 2015;5(12):3612-23IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de